Ross C. Donehower
#142,167
Most Influential Person Now
Ross C. Donehower's AcademicInfluence.com Rankings
Ross C. Donehowerphilosophy Degrees
Philosophy
#7463
World Rank
#10683
Historical Rank
Logic
#4510
World Rank
#5819
Historical Rank

Ross C. Donehowerbiology Degrees
Biology
#10130
World Rank
#13428
Historical Rank
Immunology
#630
World Rank
#651
Historical Rank
Molecular Biology
#1444
World Rank
#1471
Historical Rank

Download Badge
Philosophy Biology
Ross C. Donehower's Degrees
- Doctorate Medicine University of Pennsylvania
- PhD Molecular Biology University of Pennsylvania
Why Is Ross C. Donehower Influential?
(Suggest an Edit or Addition)Ross C. Donehower's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade (2017) (4313)
- PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. (2015) (3718)
- PD-1 blockade in tumors with mismatch repair deficiency. (2015) (2914)
- Drug therapy : paclitaxel (Taxol) (1995) (1275)
- Hypersensitivity reactions from taxol. (1990) (1093)
- Taxol: a novel investigational antimicrotubule agent. (1990) (1057)
- Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. (1989) (885)
- Clinical toxicities encountered with paclitaxel (Taxol). (1993) (694)
- The current status of camptothecin analogues as antitumor agents. (1993) (623)
- Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation. (2001) (567)
- Paclitaxel (taxol) (1995) (513)
- Evaluation of Ipilimumab in Combination With Allogeneic Pancreatic Tumor Cells Transfected With a GM-CSF Gene in Previously Treated Pancreatic Cancer (2013) (466)
- Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer. (2005) (443)
- Microtubule changes and cytotoxicity in leukemic cell lines treated with taxol. (1988) (393)
- Cardiac disturbances during the administration of taxol. (1991) (359)
- Peripheral neuropathy from taxol and cisplatin combination chemotherapy: Clinical and electrophysiological studies (1994) (352)
- Analysis of fluorouracil-based adjuvant chemotherapy and radiation after pancreaticoduodenectomy for ductal adenocarcinoma of the pancreas: results of a large, prospectively collected database at the Johns Hopkins Hospital. (2008) (328)
- The clinical pharmacology and use of antimicrotubule agents in cancer chemotherapeutics. (1991) (318)
- Phase II study of erlotinib in patients with advanced biliary cancer. (2006) (300)
- Role of body surface area in dosing of investigational anticancer agents in adults, 1991-2001. (2002) (267)
- Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study. (2014) (250)
- Personalizing Cancer Treatment in the Age of Global Genomic Analyses: PALB2 Gene Mutations and the Response to DNA Damaging Agents in Pancreatic Cancer (2010) (242)
- Effect of P-glycoprotein expression on the accumulation and cytotoxicity of topotecan (SK&F 104864), a new camptothecin analogue. (1992) (229)
- Phase I and pharmacological study of the novel topoisomerase I inhibitor 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11) administered as a ninety-minute infusion every 3 weeks. (1994) (224)
- Neurotoxicity of Taxol. (1993) (222)
- A phase I dose escalation and bioavailability study of oral sodium phenylbutyrate in patients with refractory solid tumor malignancies. (2001) (217)
- Phase I and pharmacodynamic study of taxol in refractory acute leukemias. (1989) (207)
- A Phase I clinical and pharmacological evaluation of sodium phenylbutyrate on an 120-h infusion schedule. (2001) (206)
- Digital karyotyping identifies thymidylate synthase amplification as a mechanism of resistance to 5-fluorouracil in metastatic colorectal cancer patients. (2004) (198)
- Absorption, metabolism, and excretion of 14C-temozolomide following oral administration to patients with advanced cancer. (1999) (195)
- Phase I and pharmacologic study of paclitaxel and cisplatin with granulocyte colony-stimulating factor: neuromuscular toxicity is dose-limiting. (1993) (194)
- Phase I trial of taxol in patients with advanced cancer. (1987) (184)
- Interventions for preventing neuropathy caused by cisplatin and related compounds. (2011) (181)
- MC044h, a phase II trial of sorafenib in patients (pts) with metastatic neuroendocrine tumors (NET): A Phase II Consortium (P2C) study (2007) (179)
- A Prospective Pharmacologic Evaluation of Age-Related Toxicity of Adjuvant Chemotherapy in Women with Breast Cancer (2000) (177)
- Cytotoxic effects of topotecan combined with various anticancer agents in human cancer cell lines. (1996) (175)
- Atrasentan, an endothelin-receptor antagonist for refractory adenocarcinomas: safety and pharmacokinetics. (2002) (165)
- Incidence and prognostic impact of KRAS and BRAF mutation in patients undergoing liver surgery for colorectal metastases (2013) (161)
- An overview of the clinical experience with hydroxyurea. (1992) (156)
- Impact of prolonged infusions of the putative differentiating agent sodium phenylbutyrate on myelodysplastic syndromes and acute myeloid leukemia. (2002) (155)
- Randomized phase III multi-institutional study of TNFerade biologic with fluorouracil and radiotherapy for locally advanced pancreatic cancer: final results. (2013) (152)
- Sequences of topotecan and cisplatin: phase I, pharmacologic, and in vitro studies to examine sequence dependence. (1996) (151)
- Pharmacokinetic, oral bioavailability, and safety study of fluorouracil in patients treated with 776C85, an inactivator of dihydropyrimidine dehydrogenase. (1996) (143)
- Pharmacokinetics and pharmacodynamics of topotecan in patients with advanced cancer. (1992) (131)
- High-performance liquid chromatographic assay for taxol in human plasma and urine and pharmacokinetics in a phase I trial. (1987) (129)
- Phase I and pharmacodynamic study of the topoisomerase I-inhibitor topotecan in patients with refractory acute leukemia. (1994) (125)
- Adjuvant concurrent chemoradiation for adenocarcinoma of the distal common bile duct. (2005) (121)
- Phase I and pharmacologic study of topotecan in patients with impaired renal function. (1996) (115)
- Phase I study of ON 01910.Na, a novel modulator of the Polo-like kinase 1 pathway, in adult patients with solid tumors. (2008) (115)
- Successful re-treatment with taxol after major hypersensitivity reactions. (1993) (112)
- Phase II study of flavopiridol in patients with advanced colorectal cancer. (2003) (108)
- Development of polyploidization in taxol-resistant human leukemia cells in vitro. (1990) (107)
- Taxol toxicity. Epithelial necrosis in the gastrointestinal tract associated with polymerized microtubule accumulation and mitotic arrest (1989) (107)
- Carboplatin (NSC-241-240): an active platinum analog for the treatment of squamous-cell carcinoma of the head and neck. (1986) (104)
- Laparoscopic retroperitoneal lymph node dissection for clinical stage I nonseminomatous germ cell testicular tumors. (1999) (104)
- Integrated preclinical and clinical development of S-trans, trans-farnesylthiosalicylic acid (FTS, Salirasib) in pancreatic cancer (2012) (101)
- Impact of the putative differentiating agent sodium phenylbutyrate on myelodysplastic syndromes and acute myeloid leukemia. (2001) (100)
- The clinical pharmacology of paclitaxel (Taxol). (1993) (99)
- Clinical pharmacology of methotrexate. (1981) (98)
- Programmed death-1 blockade in mismatch repair deficient colorectal cancer. (2016) (98)
- Presence of 2,4‐diamino‐N10‐methylpteroic acid after high‐dose methotrexate (1979) (97)
- Pharmacology and toxicity of high-dose cytarabine by 72-hour continuous infusion. (1986) (94)
- Phase I study of non-replicating autologous tumor cell injections using cells prepared with or without GM-CSF gene transduction in patients with metastatic renal cell carcinoma. (1995) (87)
- Tumor targeting by conjugation of DHA to paclitaxel. (2001) (87)
- A phase I pharmacokinetic and pharmacodynamic study of the DNA methyltransferase 1 inhibitor MG98 administered twice weekly. (2003) (87)
- Analysis of circulating tumor DNA to confirm somatic KRAS mutations. (2009) (85)
- Hepatic metabolism and biliary excretion of Taxol in rats and humans. (1993) (84)
- Phase I Trial of Irinotecan, Infusional 5-Fluorouracil, and Leucovorin (FOLFIRI) with Erlotinib (OSI-774) (2004) (84)
- Taxol: twenty years later, the story unfolds. (1991) (83)
- Phase I study of docosahexaenoic acid-paclitaxel: a taxane-fatty acid conjugate with a unique pharmacology and toxicity profile. (2003) (82)
- Phase I and pharmacologic studies of topotecan in patients with impaired hepatic function. (1996) (82)
- Taxol: pharmacology, metabolism and clinical implications. (1993) (81)
- A Phase I Clinical Trial of Lethally Irradiated Allogeneic Pancreatic Tumor Cells Transfected with the GM-CSF Gene for the Treatment of Pancreatic Adenocarcinoma. The Johns Hopkins Oncology Center, Baltimore, Maryland (1998) (79)
- A Phase I Dose-Finding Study of 5-Azacytidine in Combination with Sodium Phenylbutyrate in Patients with Refractory Solid Tumors (2009) (75)
- A phase I and pharmacokinetic study of short infusions of UCN-01 in patients with refractory solid tumors. (2005) (74)
- Phase I and pharmacologic study of oral fluorouracil on a chronic daily schedule in combination with the dihydropyrimidine dehydrogenase inactivator eniluracil. (2000) (73)
- PD-1 blockade in mismatch repair deficient non-colorectal gastrointestinal cancers. (2016) (71)
- Interventions for preventing neuropathy caused by cisplatin and related compounds. (2014) (70)
- Integrated preclinical and clinical development of mTOR inhibitors in pancreatic cancer (2010) (69)
- An overview of experience with TAXOL (paclitaxel) in the U.S.A. (1993) (67)
- Interventions for preventing neuropathy caused by cisplatin and related compounds. (2007) (65)
- Competitive protein binding assay of methotrexate. (1975) (63)
- Pharmacodynamic-guided modified continuous reassessment method-based, dose-finding study of rapamycin in adult patients with solid tumors. (2008) (62)
- Combination epigenetic therapy in metastatic colorectal cancer (mCRC) with subcutaneous 5-azacitidine and entinostat: a phase 2 consortium/stand Up 2 cancer study (2017) (61)
- A phase II trial of gefitinib in patients (pts) with progressive metastatic neuroendocrine tumors (NET): A Phase II Consortium (P2C) study. (2006) (58)
- Phase I trial of bortezomib in combination with docetaxel in patients with advanced solid tumors. (2006) (56)
- Olaparib in combination with irinotecan, cisplatin, and mitomycin C in patients with advanced pancreatic cancer (2017) (56)
- Phase I dose-escalation study to examine the safety and tolerability of LY2603618, a checkpoint 1 kinase inhibitor, administered 1 day after pemetrexed 500 mg/m2 every 21 days in patients with cancer (2013) (55)
- Disposition of docosahexaenoic acid-paclitaxel, a novel taxane, in blood: in vitro and clinical pharmacokinetic studies. (2003) (55)
- Phase I and pharmacologic study of high doses of the topoisomerase I inhibitor topotecan with granulocyte colony-stimulating factor in patients with solid tumors. (1996) (54)
- A phase I clinical trial of lethally irradiated allogeneic pancreatic tumor cells transfected with the GM-CSF gene for the treatment of pancreatic adenocarcinoma. (1998) (54)
- Phase I and pharmacologic study of sequences of paclitaxel and cyclophosphamide supported by granulocyte colony-stimulating factor in women with previously treated metastatic breast cancer. (1996) (54)
- Phase I trial of the matrix metalloproteinase inhibitor BAY12-9566 in patients with advanced solid tumors (2001) (52)
- A multicenter analysis of GTX chemotherapy in patients with locally advanced and metastatic pancreatic adenocarcinoma (2011) (51)
- Clinical pharmacology and metabolism of Taxol (paclitaxel): update 1993. (1994) (50)
- Phase I and pharmacological study of the pulmonary cytotoxin 4-ipomeanol on a single dose schedule in lung cancer patients: hepatotoxicity is dose limiting in humans. (1993) (48)
- A phase I and pharmacological study of topotecan infused over 30 minutes for five days in patients with refractory acute leukemia. (1996) (48)
- New developments on the mechanisms of action of antineoplastic drugs. (1979) (48)
- Adjuvant concurrent chemoradiation for node-positive adenocarcinoma of the duodenum. (2007) (47)
- Adjuvant chemoradiation versus surgery alone for adenocarcinoma of the ampulla of Vater. (2009) (45)
- In vivo cell growth and pharmacologic determinants of clinical response in acute myelogenous leukemia. (1989) (44)
- Phase I and pharmacokinetic study of UCN-01 in combination with irinotecan in patients with solid tumors (2008) (44)
- Sequence-dependent cytotoxic effects due to combinations of cisplatin and the antimicrotubule agents taxol and vincristine (2005) (43)
- Intensified adjuvant combined modality therapy for resected periampullary adenocarcinoma: acceptable toxicity and suggestion of improved 1-year disease-free survival. (2000) (41)
- Phase I and pharmacologic study of hexamethylene bisacetamide in patients with advanced cancer. (1986) (41)
- Phase I study and pharmacodynamics of piroxantrone (NSC 349174), a new anthrapyrazole. (1990) (40)
- Sixteen-week dose-intense chemotherapy in the adjuvant treatment of breast cancer. (1990) (39)
- A phase I trial of vertical inhibition of IGF signalling using cixutumumab, an anti-IGF-1R antibody, and selumetinib, an MEK 1/2 inhibitor, in advanced solid tumours (2014) (39)
- Should anticancer drug doses be adjusted in the obese patient? (1995) (38)
- Exposure-response analysis of rilotumumab in gastric cancer: the role of tumour MET expression (2015) (38)
- Demonstration of the cell cycle positions of taxol-induced "asters" and "bundles" by sequential measurements of tubulin immunofluorescence, DNA content, and autoradiographic labeling of taxol-sensitive and -resistant cells. (1989) (38)
- Phase II Study of 4-Ipomeanol, a Naturally Occurring Alkylating Furan, in Patients with Advanced Hepatocellular Carcinoma (2004) (37)
- Phase I and pharmacologic studies of pyrazoloacridine, a novel DNA intercalating agent, on single-dosing and multiple-dosing schedules. (1995) (36)
- Effects of rhGM-CSF on intracellular ara-C pharmacology in vitro in acute myelocytic leukemia: comparability with drug-induced humoral stimulatory activity. (1990) (35)
- Relation between age and clearance rate of nine investigational anticancer drugs from phase I pharmacokinetic data (2004) (35)
- Prolonged infusion of hexamethylene bisacetamide: a phase I and pharmacological study. (1987) (34)
- A phase 2 study of GVAX colon vaccine with cyclophosphamide and pembrolizumab in patients with mismatch repair proficient advanced colorectal cancer (2019) (34)
- Evaluation of the novel mitotic modulator ON 01910.Na in pancreatic cancer and preclinical development of an ex vivo predictive assay (2009) (34)
- Phase II trial of carboplatin in non-small cell lung cancer. (1986) (33)
- The Clinical Development of Paclitaxel: A Successful Collaboration of Academia, Industry and the National Cancer Institute (1996) (32)
- Hepatic toxicity of low doses of mithramycin in hypercalcemia. (1984) (31)
- 6504 ORAL Safety and Efficacy of Epirubicin, Cisplatin, and Capecitabine (ECX) Plus Rilotumumab (R) as First-line Treatment for Unresectable Locally Advanced (LA) or Metastatic (M) Gastric or Esophagogastric Junction (EGJ) Adenocarcinoma (2011) (30)
- Phase I trial of weekly trabectedin (ET-743) and gemcitabine in patients with advanced solid tumors (2008) (30)
- Phase I trial of trimetrexate glucuronate on a five-day bolus schedule: clinical pharmacology and pharmacodynamics. (1989) (30)
- Phase 2 study of erlotinib combined with adjuvant chemoradiation and chemotherapy in patients with resectable pancreatic cancer. (2013) (30)
- Reversibility of high-affinity binding of methotrexate in L1210 murine leukemia cells. (1978) (29)
- Cytotoxic synergy between pyrazoloacridine (NSC 366140) and cisplatin in vitro: inhibition of platinum-DNA adduct removal. (1997) (28)
- Taxol toxicity. Epithelial necrosis in the gastrointestinal tract associated with polymerized microtubule accumulation and mitotic arrest. (1989) (28)
- Correlation of drug-perturbed marrow cell growth kinetics and intracellular 1-B-D-arabinofuranosylcytosine metabolism with clinical response in adult acute myelogenous leukemia. (1987) (26)
- A Phase I Study of EKB-569 in Combination with Capecitabine in Patients with Advanced Colorectal Cancer (2008) (26)
- A Phase Ib/II Study of the JAK1 Inhibitor, Itacitinib, plus nab‐Paclitaxel and Gemcitabine in Advanced Solid Tumors (2018) (25)
- Camptothecin analogues: studies from The Johns Hopkins Oncology Center (2004) (24)
- Biochemical interactions between N-(phosphonacetyl)-L-aspartate and 5-fluorouracil. (1982) (24)
- Preliminary results of a phase II trial of gefitinib in progressive metastatic neuroendocrine tumors (NET): A Phase II Consortium (P2C) study (2005) (24)
- Phase II Trial of erlotinib (OSI-774) in patients with hepatocellular or biliary cancer. (2004) (22)
- Phase I and pharmacological study of CI-980, a novel synthetic antimicrotubule agent. (1997) (22)
- Phase I-phase II trial of N-phosphonacetyl-L-aspartic acid given by intravenous infusion and 5-fluorouracil given by bolus injection. (1982) (21)
- A Phase I study of the oral antimetabolite, CS-682, administered once daily 5 days per week in patients with refractory solid tumor malignancies (2006) (21)
- Correlation of Smad4 status with outcomes in patients receiving erlotinib combined with adjuvant chemoradiation and chemotherapy after resection for pancreatic adenocarcinoma. (2013) (21)
- Phase I trial of oxaliplatin, infusional 5-fluorouracil, and leucovorin (FOLFOX4) with erlotinib and bevacizumab in colorectal cancer. (2010) (21)
- Tastes associated with parenteral chemotherapy for breast cancer. (1985) (21)
- Long‐term survival benefit of upfront chemotherapy in patients with newly diagnosed borderline resectable pancreatic cancer (2017) (20)
- Is HIF-1α a Valid Therapeutic Target? (2003) (20)
- Combined effects of methotrexate and 5-fluoropyrimidine on human breast cancer cells in serum-free culture. (1980) (20)
- Sequence-dependent hematological toxicity associated with the 3-hour paclitaxel/cyclophosphamide doublet. (1998) (20)
- Immune-Related Adverse Events Requiring Hospitalization: Spectrum of Toxicity, Treatment, and Outcomes. (2019) (20)
- Solitary, isolated metastasis from Ewing's sarcoma to the brain: case report. (1991) (20)
- Evolving therapies: Farnesyltransferase inhibitors (2002) (19)
- Phase I pharmacokinetic and pharmacodynamic study of cetuximab, irinotecan and sorafenib in advanced colorectal cancer (2013) (19)
- Longer Course of Induction Chemotherapy Followed by Chemoradiation Favors Better Survival Outcomes for Patients With Locally Advanced Pancreatic Cancer (2016) (19)
- A tolerability and pharmacokinetic study of adjuvant erlotinib and capecitabine with concurrent radiation in resected pancreatic cancer. (2010) (18)
- Hexamethylene bisacetamide in myelodysplastic syndrome: effect of five-day exposure to maximal therapeutic concentrations. (1992) (17)
- A phase I and pharmacologic study of DMP 840 administered by 24-hour infusion. (1998) (16)
- A phase II "window" study of topotecan in untreated patients with high risk adult acute lymphoblastic leukemia. (1998) (16)
- Plasma methotrexate levels in patients with gestational trophoblastic neoplasia treated by two methotrexate regimens. (1984) (15)
- Effects of the differentiating agent hexamethylene bisacetamide on normal and myelodysplastic hematopoietic progenitors. (1990) (15)
- Treatment of metastatic breast cancer with combination paclitaxel/cyclophosphamide. (1995) (15)
- A phase I and pharmacologic evaluation of the DNA intercalator CI-958 in patients with advanced solid tumors. (2000) (15)
- Clinical pharmacology of oral and i.v. N-methylformamide: a pharmacologic basis for lack of clinical antineoplastic activity. (1988) (14)
- Phase II study of N-methylformamide, spirogermanium, and 4-demethoxydaunorubicin in the treatment of non-small cell lung cancer (EST 3583): an Eastern Cooperative Oncology Group study. (1989) (14)
- A phase I trial of spirohydantoin mustard (NSC 172112) in patients with advanced cancer. (1986) (14)
- Phase I study of N-methylformamide in patients with advanced cancer. (1985) (14)
- The effects of food and divided dosing on the bioavailability of oral vinorelbine (1996) (13)
- Familial GI Stromal Tumor With Loss of Heterozygosity and Amplification of Mutant KIT. (2016) (13)
- Is HIF-1 alpha a valid therapeutic target? (2003) (12)
- Integrated development of s-trans, trans-farnesylthiosalicyclic acid (FTS, salirasib) in advanced pancreatic cancer. (2008) (12)
- A phase I study of menogaril in patients with advanced cancer. (1987) (12)
- Validation and implementation of a liquid chromatography/tandem mass spectrometry assay to quantitate ON 01910.Na, a mitotic progression modulator, in human plasma. (2007) (11)
- Phase I and pharmacologic study of penclomedine, a novel alkylating agent, in patients with solid tumors. (1997) (11)
- Phase I study of ON-01910.Na, a novel cell cycle inhibitor in adult patients with solid tumors. (2006) (11)
- Thymidylate synthase (TYMS) enhancer region genotype-directed phase II trial of oral capecitabine for 2nd line treatment of advanced pancreatic cancer (2011) (10)
- High-dose topotecan with granulocyte-colony stimulating factor in fluoropyrimidine-refractory colorectal cancer: a phase II and pharmacodynamic study. (1998) (10)
- An International Phase 2 Study of Pazopanib in Progressive and Metastatic Thyroglobulin Antibody Negative Radioactive Iodine Refractory Differentiated Thyroid Cancer. (2020) (10)
- Phase I trial of bortezomib (PS-341) in combination with docetaxel in patients with advanced solid tumors. (2004) (10)
- Challenges of the current precision medicine approach for pancreatic cancer: A single institution experience between 2013 and 2017 (2020) (9)
- The practical benefits of pharmacokinetics in the use of antineoplastic agents (2004) (9)
- Phase 1 Study of ABT‐751 in Combination With CAPIRI (Capecitabine and Irinotecan) and Bevacizumab in Patients With Advanced Colorectal Cancer (2016) (9)
- A study to assess the pharmacokinetics (PK) of a single infusion of cetuximab (IMC-C225). (2004) (8)
- Phase 1 pharmacokinetic and pharmacodynamic study of the histone deacetylase inhibitor MS-275 in combination with 13-cis retinoic acid in patients with advanced solid tumors. (2006) (8)
- Tissue and tumor distribution of C-penclomedine in rats. (1996) (8)
- Nifedipine and oncologic Raynaud phenomenon. (1988) (7)
- HIV infection presenting as an unusually large pure yolk sac tumor of the testis. (2000) (7)
- Phase 2 study of programmed death-1 antibody (anti-PD-1, MK-3475) in patients with microsatellite unstable (MSI) tumors. (2014) (7)
- A phase I dose-escalation study of INCB028060, an inhibitor of c-MET receptor tyrosine kinase, in patients with advanced solid tumors. (2011) (7)
- Exposure-response (E-R) analysis of rilotumumab (R, AMG 102) plus epirubicin/cisplatin/capecitabine (ECX) in patients (pts) with locally advanced or metastatic gastric or esophagogastric junction (G/EGJ) cancer. (2012) (7)
- Phase I and pharmacokinetic study of hepsulfam (NSC 329680). (1991) (7)
- An in vitro model to predict clinical response in adult acute myelogenous leukemia. (1987) (7)
- The role of plasma level monitoring in cancer chemotherapy (1981) (7)
- Metabolism and urinary excretion of a new quinoline anticancer drug, TAS-103, in humans (2002) (7)
- A Phase I and Pharmacologic Study of Pyrazoloacridine and Cisplatin in Patients with Advanced Cancer (2003) (7)
- Local toxicity of piroxantrone: an anthrapyrazole with irritant and vesicant properties similar to those of doxorubicin. (1989) (6)
- Gastrointestinal tumors, non-colorectal (2012) (6)
- Metabolic conversion of methotrexate in man. (1980) (6)
- Recent clinical advances with camptothecin analogues. (1995) (6)
- Updated Efficacy, Biomarker, and Exposure-Response Data from a Phase 2 Study of Rilotumumab (R) Plus Epirubicin, Cisplatin, and Capecitabine (ECX) in Gastric (G) or Esophagogastric Junction (EGJ) Cancer (2012) (6)
- Hexamethylene bisacetamide-induced cutaneous vasculitis. (1987) (6)
- Growing Pains: a Simulation-Based Curriculum for Improving the Transition to Hematology/Oncology Fellowship (2017) (6)
- Pretreatment H2 receptor antagonists that differ in P450 modulation activity: comparative effects on paclitaxel clearance rates and neutropenia (1995) (6)
- Absorption, Metabolism, and Excretion of C-Temozolomide following Oral Administration to Patients with Advanced Cancer (1999) (6)
- O-0011 Evaluation of Met-Pathway Biomarkers in a Phase 2 Study of Rilotumumab Plus Epirubicin, Cisplatin, and Capecitabine in Gastric/Esophagogastric Junction Cancer (2012) (6)
- Phase II Studies (1990) (5)
- Make quality cancer survivorship care possible in the era of workforce shortage. (2010) (5)
- Direct relationship of marrow cell growth and 1-beta-D-arabinofuranosylcytosine metabolism. (1984) (5)
- Single-board hematology fellowship track: a 10-year institutional experience. (2018) (5)
- A phase 1b/2 study of INCB039110 + nab-paclitaxel (N) and gemcitabine (G) in patients (pts) with advanced solid tumors and pancreatic cancer (PC). (2017) (5)
- Effects of the leucovorin shortage: Pilot study investigating cost, efficacy, and toxicity comparison of low fixed-dose versus body surface area-adjusted leucovorin dosing in patients with resectable colon or metastatic colorectal cancer (2017) (5)
- A phase I trial of trimetrexate glucuronate (NSC 352122) given every 3 weeks: clinical pharmacology and pharmacodynamics (2004) (5)
- A phase II study of GVAX colon vaccine with cyclophosphamide and pembrolizumab in patients with mismatch repair–proficient (MMR-p) advanced colorectal cancer. (2019) (5)
- Understanding trimetrexate toxicity. (1988) (4)
- Evaluating cancer chemotherapy by infusion. (1990) (4)
- Vinorelbine and the topoisomerase 1 inhibitors: Current and potential roles in breast cancer chemotherapy (2004) (4)
- 4 Metabolism and pharmacology of taxoids (1995) (4)
- Phase I study of continuous weekly dosing of dimethylamino benzoylphenylurea (BPU) in patients with solid tumours. (2007) (4)
- Clinical and pharmacologic reappraisal of dichloromethotrexate. (1988) (4)
- Phase II trial of menogaril as initial chemotherapy for metastatic breast cancer. (1990) (4)
- Evaluation of weekly escalating doses of dichloromethotrexate in patients with hepatocellular carcinoma and other solid tumors (2004) (4)
- Pretreatment H2 receptor antagonists that differ in P450 modulation activity: comparative effects on paclitaxel clearance rates and neutropenia (1995) (4)
- A multicenter review of gemcitabine, docetaxel, and capecitabine (GTX) in patients with advanced pancreatic adenocarcinoma. (2010) (3)
- Phase I study of troxacitabine administered by continuous infusion in subjects with advanced solid malignancies. (2008) (3)
- Safety and pharmacokinetics (PK) of T138067 (T67) administered as a weekly 3-hour infusion in subjects with hepatocellular carcinoma (HCC) in a phase 1 study. (2004) (3)
- [30] Competitive protein binding assay of methotrexate (1982) (3)
- A phase I, single-institution open-label, dose-escalation trial with an expansion cohort evaluating the safety and tolerability of AZD6244 and IMC-A12 in subjects with advanced solid malignancies. (2011) (3)
- Sequence dependent effects of methotrexate (MTX) and 5-fluoropyrimidine (5-FP) in serum-free cultures of human breast cancer (1979) (3)
- Development of a canine chemotherapeutic model with ifosfamide. (1996) (2)
- Bioavailablility of penclomedine and systemic exposure to 4-O-demethylpenclomedine in patients receiving oral and intravenous penclomedine (2001) (2)
- Trainee-Led Quality Improvement Project to Improve Fertility Preservation Counseling for Patients With Cancer. (2021) (2)
- Therapeutic modalities: Editorial overview (1990) (2)
- A Phase I Tolerability and Pharmacokinetic Study of Adjuvant Erlotinib (E) and Capecitabine (Cap) with Concurrent Radiation (RT) in Resected Pancreatic Cancer (PanCa) (2008) (2)
- Incidence and prognostic impact of KRAS and BRAF mutations in patients undergoing liver surgery for colorectal metastases. (2012) (2)
- A multivariate model for identifying risk of early death after Pancreaticoduodenectomy(PDD) and adjuvant therapy for periampullary Adenocarcinoma(PA): importance for understanding post treatment outcomes (2002) (2)
- Spotlight on Clinical Response Personalizing Cancer Treatment in the Age of Global Genomic Analyses : PALB 2 Gene Mutations and the Response to DNA Damaging Agents in Pancreatic Cancer (2011) (2)
- Across the cancer continuum: A communication skills curriculum for oncology fellows. (2014) (2)
- A phase II study of combination epigenetic therapy in metastatic colorectal cancer (mCRC): A phase II consortium (P2C)/Stand Up 2 Cancer (SU2C) study. (2013) (2)
- Modeling the combined efficacy of rilotumumab (R; AMG 102) plus epirubicin/cisplatin/capecitabine (ECX) for the treatment of locally advanced or metastatic gastric or esophagogastric junction (G/EGJ) cancer. (2012) (2)
- Role of oral chemotherapy in colorectal cancer. (2000) (2)
- Cancer-Associated Neuropathic Pain and Paraneoplastic Syndromes (2012) (2)
- Sequential methotrexate and 5-fluorouracil in advanced ovarian carcinoma. (1987) (1)
- Phase I-II trial of N-phosphonacetyl-L-aspartate (PALA) and 5-fluorouracil (5FU) (1981) (1)
- Assessment of N-methylformamide (NMF) administered orally on a three times weekly schedule: a phase I study (1989) (1)
- 516 A phase 1 dose-escalation study to examine the safety and tolerability of LY2603618 administered 1 day after pemetrexed 500 mg/m2 every 21 days in patients with cancer (2010) (1)
- RAD51B Harbors Germline Mutations Associated With Pancreatic Ductal Adenocarcinoma. (2022) (1)
- A trainee-led quality improvement project to improve fertility preservation counseling and access to fertility preservation services for persons with cancer. (2021) (1)
- Taxol (T): An active new drug in ovarian epithelial cancer (OVCA) (1989) (1)
- Direct Relationship of Marrow Cell Growth and 1-/?-D-Arabinofuranosy Icytosine Metabolism1 (2006) (1)
- A phase II trial of low-dose multiagent chemotherapy with gemcitabine, docetaxel, capecitabine, and cisplatin (GTX-C) in patients with metastatic pancreatic cancer. (2014) (1)
- Microtubule changes and cytotoxicity produced by taxol in human ovarian cell lines (1987) (1)
- 430 Phase I and pharmacokinetic study of UCN-01 (U) in combination with irinotecan (I) in patients with solid tumors (2004) (1)
- Durable Responses to PD-1 Blockade in Mismatch-Repair Deficient Cancers, Independent of Tissue Origin (2017) (1)
- A Phase I Dose Escalation and Bioavailability Study of Oral Sodium Phenylbutyrate in Patients with Refractory Solid Tumor Malignancies 1 (2001) (1)
- A Phase I Clinical and Pharmacological Evaluation of Sodium Phenylbutyrate on an 120-h Infusion Schedule 1 (2001) (1)
- Intensified adjuvant therapy for periampullary (pancreatic, nonpancreatic) adenocarcinoma using irradiation, 5FU, mitomycin C, leucovorin and dipyridamole (J9625)-update results (2000) (0)
- Chemotherapy-induced diarrhea in older patients with colorectal cancer receiving fluoropyrimidines: A retrospective review. (2013) (0)
- A phase I study of NPC-1C, a novel therapeutic antibody to treat pancreas and colorectal cancers. (2011) (0)
- 207 A phase II study of intensified adjuvant therapy for resected pancreatic and other periampullary adenocarcinoma using radiation, 5Fu, leucovorin, dipyridamole and mitomycin-C (1999) (0)
- LAPAROSCOPIC RETROPERITONEAL LYMPH NODE DISSECTION (RPLND) FOR CLINICAL STAGE I NONSEMINOMATOUS GERM CELL TESTICULAR TUMORS (NSGCT) (1999) (0)
- AB095. P069. Identification of therapeutic genomic alterations by investigating cancer-related genes and microsatellite instability: road to precision medicine for pancreatic ductal adenocarcinoma (2018) (0)
- Pharmacologic, Pre-clinical and Clinical Investigations of the Cisplatin/Taxol Combination (1991) (0)
- Growing Pains: a Simulation-Based Curriculum for Improving the Transition to Hematology/Oncology Fellowship (2016) (0)
- Phase I and Pharmacokinetic Study of Brequinar Sodium (NSC 368390)1 (2006) (0)
- Hematology/medical oncology fellow responses to the initial development of an antiracism curriculum. (2021) (0)
- Abstract B74: A Phase I trial of vertical inhibition of IGF signaling using IMC-A12, an IGF1-R inhibitor, and AZD6244, a MEK 1/2 inhibitor, in patients with advanced solid tumors. (2013) (0)
- Innovation in recruitment and curricular design for diversity, equity, and inclusion (DEI) education for hematology-oncology (HO) trainees. (2022) (0)
- Evaluation of escalating doses of dichloromethotrexate (DCM) with pharmacokinetic analysis in patients with hepatocellular carcinoma and other solid tumors (1982) (0)
- Glutathione gsh content glutathione s transferase gst profiles and melphalan m sensitivity in murine hematopoietic cell lines (1988) (0)
- Methotrexate interaction with 5-fluorouracil and 5-fluorodeoxyuridine in serum-free cultures of human breast cancer (1978) (0)
- Improving resident education on the inpatient solid tumor oncology rotation through development of an asynchronous video curriculum. (2022) (0)
- Reflection rounds to facilitate resilience in hematology/medical oncology fellows. (2020) (0)
- Therapeutic modalities. (1993) (0)
- Evaluation of vinblastine and bleomycin as second-line therapy in advanced ovarian carcinoma (1984) (0)
- Atrasentan, a n E ndothelin-Recep tor A ntagonist f or Refractory A denocarcinomas: S afety a nd P harmacokinetics (2013) (0)
- 366 Evaluation of Gefitinib biological effects in patients with solid tumors amenable to sequential biopsies (2004) (0)
- Phase I and Pharmacokinetic Study of Hepsulfam ( NSC 329680 ) 1 (2006) (0)
- Resident Inpatient Curriculum for Oncology (RICO): Results of a targeted needs assessment performed in the Osler Internal Medicine Residency Program. (2022) (0)
- Drug enzyme interaction in intact tumor cells (1977) (0)
- Therapeutic modalities. (1991) (0)
- Understanding Trimetrexate Toxicity 1 (2005) (0)
- The Johns Hopkins Molecular Tumor Board Precision Oncology elective for Medical Oncology fellows. (2021) (0)
- Cancer Therapy: Clinical A Phase I Dose-Finding Study of 5-Azacytidine in Combination with Sodium Phenylbutyrate in Patients with Refractory Solid Tumors (2009) (0)
- EVALUATING THE IMPACT OF A MULTIDISCIPLINARY SINGLE DAY CLINIC ON THE MANAGEMENT OF PANCREATIC CANCER (2007) (0)
- Phase I study of ABT-751 in combination with CAPIRI (capecitabine and irinotecan) and bevacizumab in patients with advanced colorectal cancer. (2006) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Ross C. Donehower?
Ross C. Donehower is affiliated with the following schools: